{"name": "Alethia BioTherapeutics",
 "permalink": "alethia-biotherapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/alethia-biotherapeutics",
 "homepage_url": "http://www.alethiabio.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2002,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@alethiabio.com",
 "phone_number": "514.858.7666",
 "description": "",
 "created_at": "Thu Sep 09 01:39:22 UTC 2010",
 "updated_at": "Tue Apr 02 01:41:18 UTC 2013",
 "overview": "\u003Cp\u003EAlethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       103],
      "assets/images/resized/0010/1045/101045v1-max-150x150.png"],
     [[163,
       112],
      "assets/images/resized/0010/1045/101045v1-max-250x250.png"],
     [[163,
       112],
      "assets/images/resized/0010/1045/101045v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman of Board of Directors",
    "person":
     {"first_name": "Micahel",
      "last_name": "J.Berendt",
      "permalink": "micahel-j-berendt",
      "image": null}},
   {"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Yves",
      "last_name": "Cornellier",
      "permalink": "yves-cornellier",
      "image":
       {"available_sizes":
         [[[111,
            150],
           "assets/images/resized/0022/6908/226908v1-max-150x150.png"],
          [[146,
            197],
           "assets/images/resized/0022/6908/226908v1-max-250x250.png"],
          [[146,
            197],
           "assets/images/resized/0022/6908/226908v1-max-450x450.png"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Executive Vice-President and Chief Scientific Officer",
    "person":
     {"first_name": "Mario",
      "last_name": "Filion",
      "permalink": "mario-filion",
      "image":
       {"available_sizes":
         [[[112,
            150],
           "assets/images/resized/0022/6909/226909v1-max-150x150.jpg"],
          [[150,
            200],
           "assets/images/resized/0022/6909/226909v1-max-250x250.jpg"],
          [[150,
            200],
           "assets/images/resized/0022/6909/226909v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Vice-President, Research",
    "person":
     {"first_name": "Gilles",
      "last_name": "Tremblay",
      "permalink": "gilles-tremblay",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$13.9M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020100907e698000rt\u0026r=Rss\u0026s=DJFVW",
    "source_description": "Alethia Biotherapeutics Brings Home $9.2M Series A  ",
    "raised_amount": 9200000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 9,
    "funded_day": 7,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "AgeChem Venture Fund",
         "permalink": "agechem-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0006/8086/68086v1-max-150x150.jpg"],
             [[250,
               45],
              "assets/images/resized/0006/8086/68086v1-max-250x250.jpg"],
             [[343,
               63],
              "assets/images/resized/0006/8086/68086v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BDC Venture Capital",
         "permalink": "bdc-venture-capital-2",
         "image":
          {"available_sizes":
            [[[115,
               57],
              "assets/images/resized/0001/1190/11190v1-max-150x150.png"],
             [[115,
               57],
              "assets/images/resized/0001/1190/11190v1-max-250x250.png"],
             [[115,
               57],
              "assets/images/resized/0001/1190/11190v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GO Capital Fund",
         "permalink": "go-capital-fund",
         "image":
          {"available_sizes":
            [[[150,
               15],
              "assets/images/resized/0025/6380/256380v1-max-150x150.png"],
             [[250,
               25],
              "assets/images/resized/0025/6380/256380v1-max-250x250.png"],
             [[333,
               34],
              "assets/images/resized/0025/6380/256380v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company":
        {"name": "Epicentre Technologies",
         "permalink": "epicentre-technologies",
         "image": null},
       "financial_org": null,
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://finance.yahoo.com/news/alethia-biotherapeutics-closes-4-7-161951457.html",
    "source_description": "Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program",
    "raised_amount": 4700000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 11,
    "funded_day": 2,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "AgeChem Venture Fund",
         "permalink": "agechem-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0006/8086/68086v1-max-150x150.jpg"],
             [[250,
               45],
              "assets/images/resized/0006/8086/68086v1-max-250x250.jpg"],
             [[343,
               63],
              "assets/images/resized/0006/8086/68086v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BDC Venture Capital",
         "permalink": "bdc-venture-capital-2",
         "image":
          {"available_sizes":
            [[[115,
               57],
              "assets/images/resized/0001/1190/11190v1-max-150x150.png"],
             [[115,
               57],
              "assets/images/resized/0001/1190/11190v1-max-250x250.png"],
             [[115,
               57],
              "assets/images/resized/0001/1190/11190v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GO Capital Fund",
         "permalink": "go-capital-fund",
         "image":
          {"available_sizes":
            [[[150,
               15],
              "assets/images/resized/0025/6380/256380v1-max-150x150.png"],
             [[250,
               25],
              "assets/images/resized/0025/6380/256380v1-max-250x250.png"],
             [[333,
               34],
              "assets/images/resized/0025/6380/256380v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "141, Pr\u00c3\u00a9sident-Kennedy ave.",
    "address2": "Suite SB-5100",
    "zip_code": "H2X 1Y4",
    "city": "Montr\u00c3\u00a9al, Qu\u00c3\u00a9bec",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}